| Literature DB >> 33902512 |
Britta N Torgrimson-Ojerio1, Karen S Mularski2, Madeline R Peyton3, Erin M Keast3, Asha Hassan4, Ilya Ivlev3.
Abstract
BACKGROUND: Repeated use of chemical irritants for crowd-control by local and federal law enforcement during sustained racial justice protests in the U.S. has raised concerns about potential adverse health effects. The objective of this study was to describe the health consequences of exposure to tear gas agents and associated healthcare utilization among adults reporting recent exposure to tear gas.Entities:
Keywords: Crowd-control; Health effects; Healthcare utilization; Tear gas
Mesh:
Substances:
Year: 2021 PMID: 33902512 PMCID: PMC8074355 DOI: 10.1186/s12889-021-10859-w
Source DB: PubMed Journal: BMC Public Health ISSN: 1471-2458 Impact factor: 3.295
Fig. 1Flow-diagram
Participants’ characteristics
| Category | n | % ( |
|---|---|---|
| 18–33 | 1199 | 53.1 |
| 34–50 | 706 | 31.3 |
| ≥ 51 | 122 | 5.4 |
| Prefer Not to Answer | 230 | 10.2 |
| Female/Cisgender Woman | 1151 | 51.0 |
| Male/Cisgender Man | 587 | 26.0 |
| Genderqueer, not exclusively female or male | 162 | 7.2 |
| Transgender woman | 20 | 0.9 |
| Transgender man | 33 | 1.5 |
| My gender identity is not listed here | 27 | 1.2 |
| Prefer Not to Answer | 277 | 12.3 |
| White, non-Hispanic | 1615 | 71.6 |
| All other race/ethnicity | 377 | 16.7 |
| Prefer not to answer | 265 | 11.7 |
| White | 1831 | 81.1 |
| Black | 58 | 2.6 |
| American Indian or Alaska Native | 93 | 4.1 |
| Asian/Pacific Islander | 115 | 5.1 |
| Hispanic | 174 | 7.7 |
| Prefer not to answer | 265 | 11.7 |
| At a protest | 2099 | 93.0 |
| Other (i.e., homes, community) | 158 | 7.0 |
| 1 | 398 | 17.6 |
| 2 to 4 | 1391 | 61.6 |
| ≥ 5 | 468 | 20.7 |
aRespondents may be counted in multiple race/ethnicity categories
Proportions of persons reporting health issues
| Health issues categories | Number of persons expressing health issues | Change from immediate to delayed issues | ||||||
|---|---|---|---|---|---|---|---|---|
| Either immediate or with a delay | Immediately | Delayed | ||||||
| n | % | n | % | n | % | n | % | |
| Any physical or psychological health issues | 2116 | 93.8 | 2105 | 93.3 | 1944 | 86.1 | −161 | −7.6 |
| Any physical health issuesa | 2114 | 93.7 | 2105 | 93.3 | 1823 | 80.8 | − 282 | −13.4‖ |
| Eyes | 2001 | 88.7 | 1995 | 88.4 | 594 | 26.3 | − 1401 | −70.2‖ |
| Nose | 1802 | 79.8 | 1790 | 79.3 | 437 | 19.4 | − 1353 | −75.6‖ |
| Mouth | 1542 | 68.3 | 1510 | 66.9 | 378 | 16.7 | − 1132 | −75.0‖ |
| Lungs and/or Chest | 1674 | 74.2 | 1569 | 69.5 | 1063 | 47.1 | − 506 | −32.2‖ |
| Skin | 1312 | 58.1 | 1238 | 54.9 | 495 | 21.9 | − 743 | −60.0‖ |
| Gastrointestinal | 808 | 35.8 | 453 | 20.1 | 638 | 28.3 | + 185 | + 40.8‖ |
| Head | 920 | 40.8 | 610 | 27.0 | 626 | 27.7 | + 16 | + 2.6 |
| Menstrualc, d | 899 | 54.5 | N/A | 899 | 54.5 | N/A | ||
| Psychological health issues | 1635 | 72.4 | N/A | 1635 | 72.4 | N/A | ||
N/A not applicable
a Total count for the delayed physical issues includes menstrual health/breast/chest health
b Denominator was 2257 for any health issues, except 1650 for menstrual health
c Excludes cisgender men/males and transgender women
d For details for each menstrual/breast/chest health change, see Table 4 and Additional file 1
‖ p < 0.01 for the change
Proportion of respondents reporting menstrual/breast health changes according to days of exposure
| Delayed menstrual/breast/chest health issues categories | Participants reporting health issues by intensity of exposurea | |||||
|---|---|---|---|---|---|---|
| 1 day of exposure | 2–4 days of exposure | ≥5 days of exposure | ||||
| n | % | n | % | n | % | |
| Any of menstrual/breast/chest health issues | 116 | 39.7 | 566 | 54.8 | 217 | 66.6 |
| Increased menstrual cramping | 71 | 24.3 | 367 | 35.6 | 166 | 50.9 |
| Unusual spotting | 56 | 19.2 | 273 | 26.5 | 130 | 39.9 |
| Increased bleeding | 41 | 14.0 | 223 | 21.6 | 125 | 38.3 |
| Increased number of days of spotting/bleeding | 34 | 11.6 | 179 | 17.3 | 99 | 30.4 |
| Breast/chest tenderness | 23 | 7.9 | 136 | 13.2 | 74 | 22.7 |
| Increased clots | 9 | 3.1 | 85 | 8.2 | 66 | 20.2 |
| Change in the color of blood (spotting/bleeding) | 15 | 5.1 | 80 | 7.8 | 52 | 16.0 |
| Absence of menstrual bleeding | 9 | 3.1 | 66 | 6.4 | 32 | 9.8 |
| Decreased number of days of spotting/bleeding | 8 | 2.7 | 39 | 3.8 | 23 | 7.1 |
| Other | 14 | 4.8 | 66 | 6.4 | 23 | 7.1 |
a Cochran–Armitage Trend test: p < 0.01 for all menstrual/breast/chest health issues, except “Other” p = 0.18
Proportions of respondents reporting health changes by intensity of exposure
| Delayed health issues categories | Participants reporting health issues | Test of trend | ||||||
|---|---|---|---|---|---|---|---|---|
| 1 day of exposure | 2–4 days of exposure | ≥5 days of exposure | ||||||
| n | %a | n | %a | n | %a | Z value | ||
| Any physical or psychological health issues | 309 | 77.6 | 1215 | 87.3 | 420 | 89.7 | < 0.01 | − 3.8 |
| Any physical health issuesa | 290 | 72.9 | 1126 | 80.9 | 407 | 87 | < 0.01 | −4.7 |
| Eye | 91 | 22.9 | 356 | 25.6 | 147 | 31.4 | < 0.01 | −3.0 |
| Nose | 62 | 15.6 | 257 | 18.5 | 118 | 25.2 | < 0.01 | −3.8 |
| Mouth | 59 | 14.8 | 232 | 16.7 | 87 | 18.6 | 0.16 | −1.4 |
| Lungs and/or Chest | 126 | 31.7 | 648 | 46.6 | 289 | 61.8 | < 0.01 | −8.3 |
| Skin | 57 | 14.3 | 294 | 21.1 | 144 | 30.8 | < 0.01 | −5.8 |
| Gastrointestinal | 77 | 19.3 | 358 | 25.7 | 203 | 43.4 | < 0.01 | −8.5 |
| Head | 91 | 22.9 | 385 | 27.7 | 150 | 32.1 | < 0.01 | −2.8 |
| Menstrualb | 116 | 39.7 | 566 | 54.8 | 217 | 66.6 | < 0.01 | −6.0 |
| Psychological health issues | 204 | 51.3 | 1041 | 74.8 | 390 | 83.3 | < 0.01 | −8.2 |
a Total count for the delayed physical issues includes menstrual health/breast/chest health
b Denominators for exposure of 1 day, 2–4 days, and ≥ 5 days were 292; 1032, 326, respectively, because of the eligibility criteria for this outcome (see Table 4 for details)